news
The race for a new class of antibiotics
No new antibiotic class has reached market since 1987, despite 227,808 papers published since WHO released its priority pathogens list, finds study.
List view / Grid view
Antibiotics
news
First-in-class oral antibiotic improves tuberculosis
GSK’s low dose, daily oral antitubercular agent improved drug-susceptible pulmonary tuberculosis after 14 days, giving it potential as a simpler treatment option.
news
Sandoz to invest €50 million in antibiotic manufacturing facility
Sandoz will invest €50 million in new Austrian finished dosage form manufacturing site, to support the global demand for penicillin products.
news
Cystic fibrosis phage therapy trial commences
The National Institute of Allergy and Infectious Diseases (NIAID)-supported clinical trial will assess whether the bacteriophage therapy WRAIR-PAM-CF1 safely reduces the quantity of Pseudomonas aeruginos bacteria in fibrocystic lungs.
news
Is TEE the key for novel antibiotics?
Research suggests a Transferable Exclusivity Extension (TEE) system is “the only existing option capable of incentivising antibiotic R&D in a sustainable manner” for Europe.
article
Tackling the silent pandemic: AMR Industry Alliance sets the Standard
Here AMR Industry Alliance representatives Melissa Gong Mitchell and Steve Brooks discuss how the Alliance is mobilising the life sciences sector in combatting antimicrobial resistance (AMR). They present the newly established antibiotics manufacturing standard that aims to minimise pharma’s contribution to AMR in the environment, considering the critical considerations and…
news
Research calls for regulators to accelerate the approval of antibiotics
Report by One Health Trust says acknowledging antimicrobial resistance in regulatory frameworks for accelerated drug approval could improve access to new antibiotics.
news
Standard for antibiotic manufacturing to help combat AMR
The standard requires antibiotics manufacturers to have effective environmental management systems in order to minimise pharma’s role in spread of environmental antimicrobial resistance (AMR).
news
EMA issues guidance for global development of antimicrobial medicines
The European Medicines Agency (EMA) has published its final guideline on the evaluation of human medicines for the treatment of bacterial infections to help support the development of new antimicrobial medicines.
news
Could hydrophilins be the key to preventing hospital-acquired infections?
The expression of hydrophilins enables Acinetobacter baumannii to survive without water on hospital surfaces, providing a target for future elimination efforts and a pathway for biologic drug preservation.
article
The future of vaccine research and learning the lessons of COVID-19
Dr Owen Seddon, Consultant in Infectious Diseases and Medical Microbiology at University Hospital of Wales, explains how successes in the development of the coronavirus vaccine must be used in the fight against other vaccine preventable disease.
news
Coalition formed to tackle ‘hidden pandemic’ of antibiotic resistant infections
A White Paper launched by a coalition of partners spanning pharmaceuticals, MedTech and diagnostics, calls for a transformational change in the way infection is detected, monitored, prevented and managed across all facets of the NHS, healthcare systems and broader society.
news
Plasma-based engineering to accelerate antimicrobial material development
Could plasma-based engineering provide a greener method to produce antimicrobial materials, such as contact-killing, antifouling and drug-release surfaces?
article
Microneedle patch with precise vancomycin drug dose against MRSA skin infections
Effective vancomycin concentrations can be delivered locally to methicillin-resistant Staphylococcus aureus (MRSA)-infected sites of the skin with the use of miniaturised needles. This presents opportunities for targeted delivery of medication for focal skin diseases. Here, Georgios A Sotiriou and Liv Eidsmo of the Karolinska Institutet discuss some of them.
article
What to consider when formulating bacteriophages
In this article, Dr Michael Koeris, Associate Professor, Bioprocessing at Keck Graduate Institute, and Carolina Moraes de Souza, Keck MEng graduate, now Process Development Senior Associate at Amgen, discuss the key formulation considerations for bacteriophages, a potential solution to antimicrobial resistance, and why process development should be an early consideration.
